<DOC>
	<DOCNO>NCT02615873</DOCNO>
	<brief_summary>The purpose study allow evaluation long-term clinical effect safety outcome treatment AP-CD/LD , well allow patient benefit extended treatment duration AP-CD/LD successfully complete Phase 3 core study IN 11 004 ( 'core study ' , phase III , multicenter , randomize , double-blind , double-dummy , active-controlled Phase 3 study ass safety efficacy AP CD/LD versus IR CD/LD fluctuate PD patient ) .</brief_summary>
	<brief_title>A Study AP-CD/LD Fluctuating Parkinson 's Disease Patients Who Completed IN 11 004</brief_title>
	<detailed_description>This multi-center , global , open-label study adult suffer fluctuate Parkinson 's disease subject successfully complete core study IN 11 004 . After sign informed consent meeting inclusion/exclusion criterion , eligible subject enrol 12-month open-label extension receive AP-CD/LD need . Efficacy safety assess throughout study period .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Men woman PD successfully complete core study IN 11 004 2 . Subjects , opinion Investigator , PD diagnosis still valid subject remain eligible LD therapy 3 . Subjects able understand sign write informed consent participate study 1 . Participation another clinical trial receipt investigational medication within 28 day prior planned start treatment ( prior participation IN 11 004 clinical trial require ) 2 . Anticipates functional neurosurgical treatment PD ( e.g. , procedure include ablation deep brain stimulation ) study participation 3 . Received within 28 day prior Baseline Visit plan take study participation follow therapy : nonselective monoamine oxidase ( MAO ) inhibitor catecholOmethyltransferase ( COMT ) inhibitors 4 . In opinion Investigator , subject participate study</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Fluctuating Parkinson 's Disease</keyword>
	<keyword>Carbidopa</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Accordion</keyword>
</DOC>